文献速递呼吸衰竭与机械通气儿科与产科急症

微创表面活性剂治疗与假治疗对早产儿呼吸窘迫综合征死亡或支气管肺发育不良的影响:OPTIMIST-A随机临床试验

Effect of Minimally Invasive Surfactant Therapy vs Sham Treatment on Death or Bronchopulmonary Dysplasia in Preterm Infants With Respiratory Distress Syndrome: The OPTIMIST-A Randomized Clinical Trial.
PubMed 文献 · JAMA · 2021-01-01
一句话结论对CPAP支持、FiO₂≥0.30的25–28周早产儿,MIST与假治疗相比未显著降低36周死亡或BPD复合结局(RR 0.87,95%CI 0.74–1.03,P=0.10),但95%CI不能排除临床重要获益。

OPTIMIST-A多中心随机临床试验纳入485例胎龄25–28周、生后6小时内CPAP支持且FiO₂≥0.30的早产儿呼吸窘迫综合征患儿,随机接受经细导管注入猪肺磷脂α 200 mg/kg的MIST(n=241)或假治疗(n=244),之后两组继续CPAP。主要终点36周校正胎龄死亡或生理性BPD复合结局在MIST组43.6% vs 对照组49.6%(RD -6.3%,95%CI -14.2%至1.6%;RR 0.87,95%CI 0.74–1.03;P=0.10),未达统计学显著。36周前死亡无显著差异(10.0% vs 7.8%;P=0.51),但存活至36周者BPD发生率MIST组更低(37.3% vs 45.3%;RD -7.8%,95%CI -14.9%至-0.7%;RR 0.83,95%CI 0.70–0.98;P=0.03)。严重不良事件两组分别为10.3%与11.1%。作者结论认为主要复合结局未显著降低,但鉴于95%CI的统计学不确定性,不能排除临床重要效应。

要点

  • 主要复合终点(36周死亡或生理性BPD)MIST组43.6% vs 对照组49.6%,RR 0.87(95%CI 0.74–1.03),P=0.10,未达统计学显著。
  • 存活至36周者BPD发生率MIST组37.3% vs 对照组45.3%,RD -7.8%(95%CI -14.9%至-0.7%),RR 0.83(95%CI 0.70–0.98),P=0.03。
  • 36周前死亡MIST组10.0% vs 对照组7.8%,RD 2.1%(95%CI -3.6%至7.8%),RR 1.27(95%CI 0.63–2.57),P=0.51,无显著差异。
  • 严重不良事件MIST组10.3% vs 对照组11.1%。
  • 作者结论:主要复合结局未显著降低,但鉴于95%CI的统计学不确定性,不能排除临床重要效应。

适用人群与场景

  • 胎龄25至28周、生后6小时内接受CPAP支持且FiO₂≥0.30的早产儿呼吸窘迫综合征患儿。
  • 试验在33个三级新生儿重症监护病房开展,共纳入485例。

诊断标准与关键阈值

  • 纳入标准:胎龄25–28周,CPAP支持,生后6小时内FiO₂≥0.30。
  • 主要终点评估时间:36周校正胎龄。

处置流程与药物剂量

  • MIST组经细导管给予外源性表面活性剂猪肺磷脂α 200 mg/kg;对照组接受假治疗;此后两组均继续CPAP,除非达到方案规定的插管标准。

研究设计与关键结果

  • 研究类型:随机临床试验,33个三级新生儿重症监护病房,纳入485例早产儿(中位胎龄27.3周;241例[49.7%]女性),全部完成随访;入组时间2011年12月16日至2020年3月26日,随访于2020年12月2日完成。
  • 干预:MIST组(n=241)经细导管给予猪肺磷脂α 200 mg/kg vs 对照组(n=244)假治疗,两组后续继续CPAP。
  • 主要终点(36周校正胎龄死亡或生理性BPD复合结局):MIST组105例(43.6%)vs 对照组121例(49.6%),RD -6.3%(95%CI -14.2%至1.6%),RR 0.87(95%CI 0.74–1.03),P=0.10。
  • 36周前死亡:MIST组24例(10.0%)vs 对照组19例(7.8%),RD 2.1%(95%CI -3.6%至7.8%),RR 1.27(95%CI 0.63–2.57),P=0.51。
  • 存活至36周者BPD:MIST组81/217(37.3%)vs 对照组102/225(45.3%),RD -7.8%(95%CI -14.9%至-0.7%),RR 0.83(95%CI 0.70–0.98),P=0.03。
  • 严重不良事件:MIST组10.3% vs 对照组11.1%。

证据类型、等级与局限

  • 证据类型:随机临床试验(OPTIMIST-A),多中心(33个三级NICU),盲法(临床医生与结局评估者设盲)。
  • 局限:作者指出主要结局的95%CI反映统计学不确定性,不能排除临床重要效应。

对床旁实践的改变

  • 作者认为,在CPAP支持的呼吸窘迫综合征早产儿中,MIST与假治疗相比未显著降低36周死亡或BPD复合结局;鉴于95%CI的统计学不确定性,不能排除临床重要效应。

指南或共识出处

  • 试验注册:anzctr.org.au Identifier: ACTRN12611000916943

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

IMPORTANCE: The benefits of surfactant administration via a thin catheter (minimally invasive surfactant therapy [MIST]) in preterm infants with respiratory distress syndrome are uncertain.

OBJECTIVE: To examine the effect of selective application of MIST at a low fraction of inspired oxygen threshold on survival without bronchopulmonary dysplasia (BPD).

DESIGN, SETTING, AND PARTICIPANTS: Randomized clinical trial including 485 preterm infants with a gestational age of 25 to 28 weeks who were supported with continuous positive airway pressure (CPAP) and required a fraction of inspired oxygen of 0.30 or greater within 6 hours of birth. The trial was conducted at 33 tertiary-level neonatal intensive care units around the world, with blinding of the clinicians and outcome assessors. Enrollment took place between December 16, 2011, and March 26, 2020; follow-up was completed on December 2, 2020.

INTERVENTIONS: Infants were randomized to the MIST group (n = 241) and received exogenous surfactant (200 mg/kg of poractant alfa) via a thin catheter or to the control group (n = 244) and received a sham (control) treatment; CPAP was continued thereafter in both groups unless specified intubation criteria were met.

MAIN OUTCOMES AND MEASURES: The primary outcome was the composite of death or physiological BPD assessed at 36 weeks' postmenstrual age. The components of the primary outcome (death prior to 36 weeks' postmenstrual age and BPD at 36 weeks' postmenstrual age) also were considered separately.

RESULTS: Among the 485 infants randomized (median gestational age, 27.3 weeks; 241 [49.7%] female), all completed follow-up. Death or BPD occurred in 105 infants (43.6%) in the MIST group and 121 (49.6%) in the control group (risk difference [RD], -6.3% [95% CI, -14.2% to 1.6%]; relative risk [RR], 0.87 [95% CI, 0.74 to 1.03]; P = .10). Incidence of death before 36 weeks' postmenstrual age did not differ significantly between groups (24 [10.0%] in MIST vs 19 [7.8%] in control; RD, 2.1% [95% CI, -3.6% to 7.8%]; RR, 1.27 [95% CI, 0.63 to 2.57]; P = .51), but incidence of BPD in survivors to 36 weeks' postmenstrual age was lower in the MIST group (81/217 [37.3%] vs 102/225 [45.3%] in the control group; RD, -7.8% [95% CI, -14.9% to -0.7%]; RR, 0.83 [95% CI, 0.70 to 0.98]; P = .03). Serious adverse events occurred in 10.3% of infants in the MIST group and 11.1% in the control group.

CONCLUSIONS AND RELEVANCE: Among preterm infants with respiratory distress syndrome supported with CPAP, minimally invasive surfactant therapy compared with sham (control) treatment did not significantly reduce the incidence of the composite outcome of death or bronchopulmonary dysplasia at 36 weeks' postmenstrual age. However, given the statistical uncertainty reflected in the 95% CI, a clinically important effect cannot be excluded.

TRIAL REGISTRATION: anzctr.org.au Identifier: ACTRN12611000916943.

来源:JAMA,查看原文。版权归原作者所有。

参考来源

  1. Dargaville PA, Kamlin COF, Orsini F, et al. Effect of Minimally Invasive Surfactant Therapy vs Sham Treatment on Death or Bronchopulmonary Dysplasia in Preterm Infants With Respiratory Distress Syndrome: The OPTIMIST-A Randomized Clinical Trial. JAMA. 2021. PMID: 34902013. doi:10.1001/jama.2021.21892

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。